{
  "schema_version": "5.0",
  "artifact_kind": "company_profile",
  "language": "zh-CN",
  "generated_on": "2026-11-11",
  "research_as_of": "2026-11-10",
  "input_context": {
    "name_zh": "恒瑞医药",
    "name_en": "Hengrui",
    "industry_level1": "医药健康",
    "industry_level2": "",
    "official_website": "www.hengrui.com",
    "company_type": "品牌方",
    "logo_url": "https://img.logo.dev/www.hengrui.com?token=pk_C1w9wXUfQkaYSJRJ-OQSCQ&size=256&format=webp&fallback=404"
  },
  "entity": {
    "name_zh": "江苏恒瑞医药股份有限公司",
    "scope": "600276/01276上市公司及受控经营范围；瑞石保留研发品牌角色，股东集团其他医械关联方及授权合作伙伴不混入受控商品。",
    "source_ids": [
      "S01",
      "S02",
      "S03",
      "S19",
      "S20"
    ]
  },
  "basic_info": [
    {
      "key": "legal_name",
      "label": "法定主体或所属主体",
      "value": "江苏恒瑞医药股份有限公司（Jiangsu Hengrui Pharmaceuticals Co., Ltd.）",
      "source_ids": [
        "S01",
        "S03"
      ]
    },
    {
      "key": "founded",
      "label": "成立时间",
      "value": "前身连云港制药厂1970年创立；股份公司1997年4月28日登记",
      "source_ids": [
        "S01",
        "S07"
      ]
    },
    {
      "key": "headquarters",
      "label": "总部",
      "value": "中国江苏省连云港市经济技术开发区昆仑山路7号；黄河路38号为注册地，上海海科路1288号为证券事务联系地",
      "source_ids": [
        "S01",
        "S03"
      ]
    },
    {
      "key": "listing",
      "label": "上市情况",
      "value": "上海证券交易所A股600276（2000年上市）及香港联交所H股01276（2025年上市），A+H",
      "source_ids": [
        "S01",
        "S07"
      ]
    },
    {
      "key": "employees",
      "label": "员工人数",
      "value": 20744,
      "unit": "人",
      "as_of": "2026-06-30",
      "scope": "港股中期报告集团雇员总数；不取2025年末20602、教育资料20547或研发团队5600余人",
      "source_ids": [
        "S03"
      ],
      "display": "20,744人"
    },
    {
      "key": "revenue",
      "label": "营业收入",
      "value": 31629416193.83,
      "unit": "CNY",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "2025完整自然年合并全部营业收入，含销售商品28013448347.68元、许可收入3392409960.56元和其他223557885.59元",
      "source_ids": [
        "S01"
      ],
      "display": "316.29亿元人民币"
    },
    {
      "key": "current_year_revenue",
      "label": "今年营业收入",
      "value": 24408762724.19,
      "unit": "CNY",
      "period": {
        "start": "2026-01-01",
        "end": "2026-09-30",
        "basis": "calendar_year"
      },
      "scope": "前三季度未经审计累计实际收入，港股原报27日首披；不取单季8953178996.08元、许可收到现金或潜在合同总额",
      "statement_date": "2026-10-27",
      "source_ids": [
        "S04",
        "S05"
      ],
      "display": "244.09亿元人民币"
    },
    {
      "key": "international_revenue",
      "label": "国际业务收入",
      "value": 4770880508.33,
      "unit": "CNY",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "2025合并附注61按业务地区“国外”全部收入，包含许可及商品等；国内国外沿用原报划分，不改划港澳台；不同于国外主营1347940133.99和母公司国外4728432431.44",
      "source_ids": [
        "S01"
      ],
      "display": "47.71亿元人民币"
    },
    {
      "key": "international_revenue_share",
      "label": "国际收入占比",
      "value": 15.08,
      "unit": "%",
      "period": {
        "start": "2025-01-01",
        "end": "2025-12-31",
        "basis": "calendar_year"
      },
      "scope": "同口径合并国外4770880508.33/合并31629416193.83×100=15.08368%，四舍五入15.08%；计算值，非仅制剂出口占比",
      "source_ids": [
        "S01"
      ],
      "display": "15.08%"
    },
    {
      "key": "sales_coverage",
      "label": "销售覆盖国家及地区",
      "value": "-",
      "source_ids": [],
      "display": "-"
    }
  ],
  "overview": {
    "paragraphs": [
      {
        "text": "恒瑞是1970年创立、A+H上市的制药企业，研发生产推广创新药和高质量仿制药，覆盖肿瘤、代谢心血管、免疫呼吸、神经科学等，并开展有偿许可及合作研发。2026年6月底集团员工20744人。",
        "source_ids": [
          "S01",
          "S03",
          "S07",
          "S10"
        ]
      },
      {
        "text": "2025合并收入316.2942亿元，国外全部收入47.7088亿元、同口径计算占15.08%；2026前三季度累计244.0876亿元。产品已在50多个国家商业化，同时年报称50多个海外市场，净境外国数未明确统一。美国卡瑞利珠单抗组合2026年11月重新获受理，尚不是FDA上市批准。",
        "source_ids": [
          "S01",
          "S04",
          "S08",
          "S13"
        ]
      }
    ]
  },
  "business": {
    "paragraphs": [
      {
        "text": "实物包括抗肿瘤小分子/化疗药、抗体/ADC、血液及肿瘤支持药、糖尿病与心血管药、免疫炎症药、麻醉镇静镇痛药、造影介入用药、抗感染、眼科及肠外营养制剂，并有对外销售原料药。艾坦、艾瑞卡、艾维达、瑞沁、瑞恒盈、恒优达等保留药品商品名，未按剂量、临床阶段或每个适应症拆成独立业务。",
        "source_ids": [
          "S01",
          "S02",
          "S06",
          "S08",
          "S14",
          "S15",
          "S17"
        ]
      },
      {
        "text": "对外许可与合作业务已经产生实际收入，合同交付为地域化知识产权、研发和技术转移；原报未将早期合作研发单独披露为另一项收入。候选药许可不等于患者药品销售。BMS、GSK、诺和、MSD、德国默克和NewCo合作方为交易对手，不是恒瑞自有品牌；每笔地域排除和交割条件分别保留。",
        "source_ids": [
          "S01",
          "S02",
          "S04",
          "S10",
          "S11"
        ]
      },
      {
        "text": "瑞石Reistone保留孵化子公司及免疫炎症研发品牌角色，SHR0302已对应艾玛昔替尼药品，其他RSS等管线仍以最新试验状态列研发，不当已上市药。内部AIDD和研发信息系统不是已确认的独立软件、云API或对外CRO服务；苏州恒瑞医疗器械为其他关联方，集团医械与特医营养商品不因同名并入本上市公司。",
        "source_ids": [
          "S01",
          "S02",
          "S09",
          "S19",
          "S20"
        ]
      }
    ],
    "brands": [
      {
        "name": "恒瑞医药 Hengrui Pharmaceuticals",
        "description": "上市公司统一制药品牌；艾坦、艾瑞卡、艾维达、瑞沁、瑞恒盈、恒优达等为具体药品商品名，保留在代表产品，不等于一组同级法人。上海恒瑞、苏州盛迪亚、成都盛迪、福建盛迪为研发生产主体，国际合作伙伴保持交易对手角色。",
        "source_ids": [
          "S01",
          "S02",
          "S06",
          "S07"
        ],
        "website": "https://www.hengrui.com/",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "药品研发生产及许可"
          }
        ],
        "products": [
          {
            "category": "抗肿瘤小分子及化疗制剂",
            "series": [],
            "representative_products": [
              {
                "name": "艾坦（阿帕替尼）",
                "website": null
              },
              {
                "name": "艾瑞妮（吡咯替尼）",
                "website": null
              },
              {
                "name": "艾瑞颐（氟唑帕利）",
                "website": null
              },
              {
                "name": "艾瑞康（达尔西利）",
                "website": null
              },
              {
                "name": "艾瑞恩（瑞维鲁胺）",
                "website": null
              },
              {
                "name": "艾瑞璟（泽美妥司他）",
                "website": null
              },
              {
                "name": "艾比特（法米替尼）",
                "website": null
              },
              {
                "name": "白蛋白紫杉醇、伊立替康脂质体",
                "website": null
              }
            ],
            "description": "激酶、PARP、激素受体等靶向药及传统化疗、改良脂质体和白蛋白制剂；创新/仿制、注射/口服属于系列差异。",
            "source_ids": [
              "S01",
              "S02",
              "S06",
              "S08"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "抗肿瘤抗体与ADC药品",
            "series": [],
            "representative_products": [
              {
                "name": "艾瑞卡（卡瑞利珠单抗）",
                "website": null
              },
              {
                "name": "艾瑞利（阿得贝利单抗）",
                "website": null
              },
              {
                "name": "艾维达（瑞康曲妥珠单抗）",
                "website": null
              },
              {
                "name": "艾泽利（瑞拉芙普α）",
                "website": null
              }
            ],
            "description": "PD1/PDL1单抗、HER2 ADC及双特异性抗体融合蛋白等已获批品种；具体地区和适应症按批准，不把在研HER3/新靶点ADC统一写已上市。",
            "source_ids": [
              "S02",
              "S06",
              "S16"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "血液系统及肿瘤支持治疗药",
            "series": [],
            "representative_products": [
              {
                "name": "恒曲（海曲泊帕）",
                "website": null
              },
              {
                "name": "艾多（硫培非格司亭）",
                "website": null
              },
              {
                "name": "瑞坦宁（磷罗拉匹坦帕洛诺司琼）",
                "website": null
              },
              {
                "name": "恒优达（立康可泮）",
                "website": null
              }
            ],
            "description": "血小板生成素受体激动剂、升白细胞药和化疗相关止吐药，并含补体B因子抑制剂；这些不统一写成直接抗肿瘤药。",
            "source_ids": [
              "S01",
              "S02",
              "S06",
              "S15"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "糖尿病药物",
            "series": [],
            "representative_products": [
              {
                "name": "瑞沁（恒格列净）",
                "website": null
              },
              {
                "name": "瑞泽唐（瑞格列汀）",
                "website": null
              },
              {
                "name": "瑞霖唐",
                "website": null
              },
              {
                "name": "瑞沁达",
                "website": null
              },
              {
                "name": "瑞乐唐",
                "website": null
              },
              {
                "name": "瑞恒盈（舒地胰岛素）",
                "website": null
              }
            ],
            "description": "SGLT2、DPP4及二甲双胍固定复方等口服制剂和2026获批舒地胰岛素注射液；HRS7535、瑞普泊肽等申请受理仍按在研，不作已售GLP1成药。",
            "source_ids": [
              "S02",
              "S04",
              "S06",
              "S14"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "心血管、血脂与高尿酸药物",
            "series": [],
            "representative_products": [
              {
                "name": "艾心安（瑞卡西单抗）",
                "website": null
              },
              {
                "name": "瑞胜康（欧米伽3酸乙酯90）",
                "website": null
              },
              {
                "name": "瑞鸣（鲁兹诺雷钠）",
                "website": null
              }
            ],
            "description": "PCSK9抑制剂、欧米伽3酸乙酯90等血脂药及2026获批鲁兹诺雷钠等代谢相关制剂；药物靶点和同药适应症不拆品牌。",
            "source_ids": [
              "S01",
              "S02",
              "S06"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "免疫炎症与移植用药",
            "series": [],
            "representative_products": [
              {
                "name": "安达静（夫那奇珠单抗）",
                "website": null
              },
              {
                "name": "恒扬（艾瑞昔布）",
                "website": null
              },
              {
                "name": "瑞倍容（他克莫司缓释胶囊）",
                "website": null
              }
            ],
            "description": "夫那奇珠单抗、艾瑞昔布及他克莫司缓释胶囊等覆盖免疫炎症、关节疼痛与移植免疫抑制；艾玛昔替尼同时涉及瑞石平台，另说明其研发角色。",
            "source_ids": [
              "S02",
              "S06",
              "S08"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "麻醉、镇静、镇痛及神经相关制剂",
            "series": [],
            "representative_products": [
              {
                "name": "七氟烷",
                "website": null
              },
              {
                "name": "盐酸右美托咪定",
                "website": null
              },
              {
                "name": "布托啡诺",
                "website": null
              },
              {
                "name": "布比卡因脂质体",
                "website": null
              },
              {
                "name": "普瑞巴林缓释片",
                "website": null
              }
            ],
            "description": "手术与围术期麻醉镇静镇痛、局麻及慢性神经痛等制剂，包括吸入性麻醉药及长效局麻；网页精神麻醉药不展示时，以原报明确实际业务补足，不将监管隐藏当作无业务。",
            "source_ids": [
              "S01",
              "S02",
              "S08"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "造影剂与介入用药",
            "series": [],
            "representative_products": [
              {
                "name": "碘佛醇",
                "website": null
              },
              {
                "name": "碘克沙醇",
                "website": null
              },
              {
                "name": "钆布醇",
                "website": null
              },
              {
                "name": "钆特酸葡胺",
                "website": null
              }
            ],
            "description": "碘及钆类造影剂等影像诊断用药，区别于医疗影像设备或关联方介入耗材。",
            "source_ids": [
              "S01",
              "S06",
              "S08"
            ],
            "website": "https://www.hengrui.com/international/"
          },
          {
            "category": "抗感染制剂",
            "series": [],
            "representative_products": [
              {
                "name": "瑞必康（奥特康唑）",
                "website": null
              },
              {
                "name": "醋酸卡泊芬净",
                "website": null
              },
              {
                "name": "达托霉素",
                "website": null
              }
            ],
            "description": "抗真菌、抗菌制剂等，包括奥特康唑、醋酸卡泊芬净、达托霉素；具体产品按地区注册上市状态说明，不将全部研究抗感染管线写为销售药。",
            "source_ids": [
              "S02",
              "S06",
              "S08"
            ],
            "website": "https://www.hengrui.com/international/"
          },
          {
            "category": "眼科制剂",
            "series": [],
            "representative_products": [
              {
                "name": "恒宜（环孢素滴眼液Ⅳ）",
                "website": null
              }
            ],
            "description": "2026获批海外引进的0.1%无水环孢素滴眼液Ⅳ等眼科药，保留引进产品角色，非自研仪器。",
            "source_ids": [
              "S02",
              "S06"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          },
          {
            "category": "肠外营养注射制剂",
            "series": [],
            "representative_products": [],
            "description": "福建盛迪获批含ω3鱼油的脂肪乳/氨基酸/葡萄糖三腔袋复合注射液；归药品，三腔袋为剂型包装，非关联方特医食品或独立药包材销售。",
            "source_ids": [
              "S17"
            ],
            "website": "https://www.hengrui.com/media/detail-954.html"
          },
          {
            "category": "医药原料药",
            "series": [],
            "representative_products": [],
            "description": "原报明确向美国及欧洲等市场销售药品及原料药，保留2B原料商品；在建原料药生产线、化工经营范围不直接变成已售全部API清单。",
            "source_ids": [
              "S01",
              "S18"
            ],
            "website": "https://www.hengrui.com/international/"
          }
        ],
        "services": [
          {
            "name": "药物地域许可与技术转移",
            "description": "面向GSK、MSD、BMS、诺和及NewCo等交易对手，交付约定区域开发、制造、商业化权利及相关资料/技术转移，按履约确认许可收入；首付款、股权、里程碑和潜在销售分成分别说明，不当药品销量。",
            "source_ids": [
              "S01",
              "S02",
              "S04",
              "S10",
              "S11"
            ],
            "website": "https://www.hengrui.com/international/"
          },
          {
            "name": "战略合作早期药物开发",
            "description": "BMS13项目合作涵盖双方项目与共同研发项目，恒瑞负责早期临床开发和概念验证，具有具体研发对象与交付；不是仅普通售后，也不据此扩成向公众开放的全流程CRO/CDMO平台。",
            "source_ids": [
              "S10"
            ],
            "website": "https://www.hengrui.com/media/detail-950.html"
          }
        ]
      },
      {
        "name": "瑞石生物 Reistone",
        "description": "恒瑞2018年孵化的免疫炎症研发品牌；官方历史说明为子公司，2026合并境外经营实体继续列REISTONE。不沿用2022融资后旧股比及临床阶段。",
        "source_ids": [
          "S02",
          "S20"
        ],
        "website": "https://www.hengrui.com/media/detail-194.html",
        "industries": [
          {
            "level1": "医药健康",
            "level2": "免疫炎症药物研发"
          }
        ],
        "products": [
          {
            "category": "免疫炎症药物及研发管线",
            "series": [],
            "representative_products": [
              {
                "name": "艾速达（艾玛昔替尼）",
                "website": null
              }
            ],
            "description": "SHR0302对应艾玛昔替尼（艾速达），已在中国获批相关适应症；RSS0343、RSS0393等仍属研发管线，不能当零售药物。商业化药名与集团目录保持关联，不重复计为另一套药。",
            "source_ids": [
              "S02",
              "S04",
              "S06",
              "S20"
            ],
            "website": "https://www.hengrui.com/product/index.html"
          }
        ],
        "services": []
      }
    ],
    "services": []
  },
  "global_presence": {
    "paragraphs": [
      {
        "text": "制剂和原料药已进入海外市场；2025ESG明确触达孟加拉国、老挝以及肯尼亚、坦桑尼亚、津巴布韦、博茨瓦纳，北美美国有药品及原料药实际销售证据。欧洲英国、德国条目包含已确认许可业务的交易对手市场，并不表示全部创新药已在这些国家对患者销售。南美仅有区域描述，未凭全球授权范围补齐国家。",
        "source_ids": [
          "S01",
          "S08",
          "S09"
        ]
      },
      {
        "text": "年报称50多个海外市场的销售覆盖，其他章节称50多个国家商业化；公司未明确提供统一排除中国的净境外国数，未减一推算。研发临床覆盖12/13国、20个海外注册批件及孤儿药/快速通道资格均不同于销售国数。",
        "source_ids": [
          "S01",
          "S08",
          "S09"
        ]
      },
      {
        "text": "总部及中国多地工厂、美国波士顿临床研发合作中心，以及澳大利亚研发中心有实际经营描述。日本名古屋、德国Willich、瑞士巴塞尔等列为境外主体主要经营地，但本次未完整核实对应自用固定场所；苏黎世HENGRUI EUROPE BIOSCIENCE AG已在2026中期注销，不能沿用旧设施清单。临床医院、海外合作方及金融注册地不算自营设施。",
        "source_ids": [
          "S01",
          "S02",
          "S03",
          "S09"
        ]
      },
      {
        "text": "2026年三期及五期部分产业化项目有验收公示，八期、广东扩建及mRNA二期仍为规划/环评状态，未由建设公告推为全部投产；美国卡瑞利珠单抗组合重新获FDA受理仍待批准，区别于已有仿制制剂出口。",
        "source_ids": [
          "S08",
          "S13",
          "S18"
        ]
      }
    ],
    "market_regions": [
      {
        "region": "亚洲",
        "countries": [
          "孟加拉国",
          "老挝"
        ],
        "source_ids": [
          "S09"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "英国",
          "德国"
        ],
        "source_ids": [
          "S01",
          "S08",
          "S10"
        ]
      },
      {
        "region": "非洲",
        "countries": [
          "肯尼亚",
          "坦桑尼亚",
          "津巴布韦",
          "博茨瓦纳"
        ],
        "source_ids": [
          "S09"
        ]
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "source_ids": [
          "S01",
          "S08"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      }
    ],
    "operating_regions": [
      {
        "region": "亚洲",
        "countries": [
          "中国"
        ],
        "source_ids": [
          "S01",
          "S03",
          "S18"
        ]
      },
      {
        "region": "欧洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "非洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "北美洲",
        "countries": [
          "美国"
        ],
        "source_ids": [
          "S01",
          "S08"
        ]
      },
      {
        "region": "南美洲",
        "countries": [
          "-"
        ],
        "source_ids": []
      },
      {
        "region": "大洋洲",
        "countries": [
          "澳大利亚"
        ],
        "source_ids": [
          "S01",
          "S09"
        ]
      }
    ]
  },
  "developments": {
    "window": {
      "start": "2025-11-10",
      "end": "2026-11-10",
      "max_items": 5
    },
    "items": [
      {
        "id": "E01",
        "title": "卡瑞利珠单抗组合重新提交BLA获FDA受理",
        "importance": "major",
        "display_date": "2026-11-04",
        "summary": "继7月10日披露相关场地CGMP观察项导致完整回复信后，公司11月4日披露近日重新提交BLA获受理，目标审评2027年4月9日；截至基准日仍待美国上市批准。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S12",
          "S13"
        ]
      },
      {
        "id": "E02",
        "title": "HRS1596口服GLP1/GIP候选药与诺和签订许可",
        "importance": "major",
        "display_date": "2026-09-29",
        "summary": "签订大中华区（排除中国大陆、香港、澳门、台湾）以外全球独家开发、生产及商业化许可，约定3亿美元首付款、最高26亿美元潜在总额及销售提成；候选药处Ⅰ期就绪阶段，尚待反垄断等交割条件，预计第四季度交割。",
        "status": "announced",
        "source_ids": [
          "S11"
        ]
      },
      {
        "id": "E03",
        "title": "立康可泮恒优达获批国内上市",
        "importance": "major",
        "display_date": "2026-08-21",
        "summary": "成都盛迪收到补体B因子抑制剂富马酸立康可泮胶囊上市批准，用于既往未接受补体抑制剂治疗的PNH成人患者；拓展人群申请未一并写成获批。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S15"
        ]
      },
      {
        "id": "E04",
        "title": "舒地胰岛素瑞恒盈获批国内上市",
        "importance": "major",
        "display_date": "2026-07-30",
        "summary": "公司披露自主研发长效胰岛素类似物舒地胰岛素注射液获批，用于成人2型糖尿病，强化口服与注射糖尿病产品组合。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S14"
        ]
      },
      {
        "id": "E05",
        "title": "与BMS达成13项早期药物战略合作及许可",
        "importance": "major",
        "display_date": "2026-05-12",
        "summary": "双方签署涵盖4项恒瑞、4项BMS及5项共同项目的协议，恒瑞负责早期临床开发；约定6亿美元首款及周年条件付款、最高约152亿美元潜在总额。签署时待交割，三季报已确认收到6亿美元首款并按履约确认部分收入。",
        "status": "completed_per_company_statement",
        "source_ids": [
          "S02",
          "S04",
          "S10"
        ]
      }
    ]
  },
  "sources": [
    {
      "id": "S01",
      "title": "恒瑞医药｜2025年年度报告",
      "url": "https://pdf.dfcfw.com/pdf/H2_AN202603251820749693_1.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-03-25"
    },
    {
      "id": "S02",
      "title": "恒瑞医药｜2026年A股半年度报告",
      "url": "https://static.cninfo.com.cn/finalpage/2026-08-20/1225483600.PDF",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-08-20"
    },
    {
      "id": "S03",
      "title": "恒瑞医药｜2026年港股中期报告",
      "url": "https://manager.wisdomir.com/files/760/2026/0819/20260819214502_95320200_tc.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-08-19"
    },
    {
      "id": "S04",
      "title": "恒瑞医药｜2026年第三季度报告（港股10月27日首披）",
      "url": "https://manager.wisdomir.com/files/760/2026/1027/20261027164501_24814092_tc.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-10-27"
    },
    {
      "id": "S05",
      "title": "恒瑞医药｜2026年第三季度亮点盘点",
      "url": "https://www.hengrui.com/media/detail-1062.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2026-10-28"
    },
    {
      "id": "S06",
      "title": "恒瑞医药｜官网完整产品目录",
      "url": "https://www.hengrui.com/product/index.html",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S07",
      "title": "恒瑞医药｜公司概况与历史",
      "url": "https://www.hengrui.com/about/survey.html",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S08",
      "title": "恒瑞医药｜国际化、制剂出口与合作目录",
      "url": "https://www.hengrui.com/international/",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S09",
      "title": "恒瑞医药｜2025年度ESG报告（英文）",
      "url": "https://www.hengrui.com/uploads/20260402093102/f.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-04-02"
    },
    {
      "id": "S10",
      "title": "恒瑞医药｜与BMS战略合作及许可协议",
      "url": "https://www.hengrui.com/media/detail-950.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2026-05-12"
    },
    {
      "id": "S11",
      "title": "恒瑞医药｜HRS1596诺和独家许可协议",
      "url": "https://www.hengrui.com/media/detail-1041.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2026-09-29"
    },
    {
      "id": "S12",
      "title": "恒瑞医药｜卡瑞利珠单抗组合FDA完整回复信公告",
      "url": "https://manager.wisdomir.com/files/760/2026/0710/20260710140002_64625318_tc.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-07-10"
    },
    {
      "id": "S13",
      "title": "恒瑞医药｜卡瑞利珠单抗组合重新提交BLA获FDA受理",
      "url": "https://manager.wisdomir.com/files/760/2026/1104/20261104180001_50108824_tc.pdf",
      "type": "official_report",
      "accessed_on": "2026-11-11",
      "published_at": "2026-11-04"
    },
    {
      "id": "S14",
      "title": "恒瑞医药｜舒地胰岛素瑞恒盈获批上市",
      "url": "https://www.hengrui.com/media/detail-1002.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2026-07-30"
    },
    {
      "id": "S15",
      "title": "恒瑞医药｜立康可泮恒优达获批上市",
      "url": "https://www.hengrui.com/media/detail-1015.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2026-08-21"
    },
    {
      "id": "S16",
      "title": "恒瑞医药｜瑞拉芙普α艾泽利获批上市",
      "url": "https://www.hengrui.com/media/detail-901.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2026-01-08"
    },
    {
      "id": "S17",
      "title": "恒瑞医药｜含ω3鱼油三腔袋营养注射液获批上市",
      "url": "https://www.hengrui.com/media/detail-954.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2026-05-20"
    },
    {
      "id": "S18",
      "title": "恒瑞医药｜官方信息公开与生产建设公示",
      "url": "https://www.hengrui.com/about/notice.html",
      "type": "official",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S19",
      "title": "恒瑞医药｜苏州恒瑞医疗器械关于我们",
      "url": "https://www.hrmedical.com.cn/About.html",
      "type": "other",
      "accessed_on": "2026-11-11"
    },
    {
      "id": "S20",
      "title": "恒瑞医药｜瑞石生物子公司及研发角色历史说明",
      "url": "https://www.hengrui.com/media/detail-194.html",
      "type": "official_news",
      "accessed_on": "2026-11-11",
      "published_at": "2022-05-10"
    }
  ],
  "report_template": "core-v4"
}
